Compare HAL & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAL | DGX |
|---|---|---|
| Founded | 1919 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5B | 23.1B |
| IPO Year | 2006 | 1996 |
| Metric | HAL | DGX |
|---|---|---|
| Price | $38.04 | $197.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 13 |
| Target Price | $34.71 | ★ $208.62 |
| AVG Volume (30 Days) | ★ 15.3M | 623.9K |
| Earning Date | 04-21-2026 | 04-21-2026 |
| Dividend Yield | ★ 1.78% | 1.74% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | 0.81 | ★ 8.75 |
| Revenue | ★ $17,973,000,000.00 | $11,035,000,000.00 |
| Revenue This Year | N/A | $7.53 |
| Revenue Next Year | $3.74 | $3.77 |
| P/E Ratio | $47.06 | ★ $22.63 |
| Revenue Growth | ★ 22.47 | 11.78 |
| 52 Week Low | $18.72 | $157.20 |
| 52 Week High | $41.18 | $213.50 |
| Indicator | HAL | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 58.37 | 49.57 |
| Support Level | $33.20 | $194.77 |
| Resistance Level | N/A | $203.96 |
| Average True Range (ATR) | 1.33 | 4.26 |
| MACD | 0.09 | -0.17 |
| Stochastic Oscillator | 60.56 | 51.96 |
Halliburton is North America's largest oilfield-services company as measured by market share. Despite industry fragmentation, it holds a leading position in the hydraulic fracturing and completions market, which makes up nearly half of its revenue. It also holds strong positions in other service offerings like drilling and completions fluids, which leverages its expertise in material science, as well as the directional drilling market. While we consider SLB the global leader in reservoir evaluation, we think Halliburton leads in any activity from the reservoir to the wellbore. Halliburton's innovations have helped multiple producers lower their development costs per barrel of oil equivalent, with techniques that have been honed over a century of operations.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.